Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | NPEPPS | P55786 | 3/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28821343 | 0.94 | NSD2 (0.36) | NSD2LMNASMN1; SMN2SLC29A1NPEPPS | |
| SCHEMBL28821345 | 0.94 | NSD2 (0.36) | NSD2LMNASMN1; SMN2SLC29A1NPEPPS | |
| SCHEMBL31028274 | 0.90 | LMNA (0.36) | NSD2LMNASMN1; SMN2SLC29A1NPEPPS | |
| SCHEMBL24075638 | 0.85 | LMNA (0.38) | NSD2LMNASMN1; SMN2SLC29A1FGFR1 | |
| SCHEMBL28821413 | 0.84 | LMNA (0.36) | NSD2LMNASMN1; SMN2SLC29A1NPEPPS | |
| SCHEMBL28821417 | 0.84 | LMNA (0.36) | NSD2LMNASMN1; SMN2SLC29A1NPEPPS | |
| SCHEMBL31028254 | 0.84 | P2RX3 (0.39) | SLC29A1FGFR1FGFR4P2RX3AAK1 | |
| SCHEMBL28821449 | 0.83 | P2RX3 (0.36) | SLC29A1FGFR1FGFR4P2RX3AAK1 | |
| SCHEMBL24075627 | 0.83 | P2RX3 (0.36) | SLC29A1FGFR1FGFR4P2RX3AAK1 | |
| SCHEMBL29727327 | 0.83 | P2RX3 (0.36) | SLC29A1FGFR1FGFR4P2RX3AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-4013754-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | NSD2 105/4885LMNA 2414/4885SMN1; SMN2 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.